Covidien announced that it will launch the TurboHawk plaque excision system for small vessels in March 2011 in the United States and several international markets. The new system expands minimally invasive treatment options for peripheral arterial disease with the treatment of calcified and non-calcified lesion morphologies in small vessels. The device received 510(k) clearance from the FDA in January 2011.
The design of TurboHawk allows for greater cutting efficiency, providing physicians access to a device with more consistent performance. The minimally invasive nature of the procedure may lead to faster recovery and shorter hospital visits for patients.
“The TurboHawk system for small vessels extends the capabilities demonstrated by TurboHawk Super and Smooth Cutter above the knee to smaller, below the knee vessels. This translates to improved delivery and improved plaque excision of mild to moderately calcified vessels,” said Stacy Enxing Seng, president, Peripheral Vascular, Covidien.
“The TurboHawk plaque excision system for small vessels will provide physicians and healthcare professionals with a minimally invasive solution that can improve patient outcomes in the treatment of peripheral arterial disease,” said Joe Woody, president, Vascular Therapies, Covidien.
